Biotest (BIO3) AI Stock Analysis

• Market Cap: €1.35B
• Dividend Yield: 0.14%
• Average Volume (3M): 867.00
• Price to Earnings (P/E): 45.0
• Beta (1Y): -0.03
• Revenue Growth: -18.82%
• EPS Growth: -113.85%
• Country: DE
• Employees: 2,495
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 19,785,727
• 10 Day Avg. Volume: 363
• 30 Day Avg. Volume: 867
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €31.00
• Price Target Upside: 6.90% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 56 Neutral
• Price Target: €30.00 ▲(3.45% Upside)

The overall stock score is primarily influenced by stable financial performance with some risks, including high leverage and declining net profit margins. Technical analysis indicates a bearish trend, and valuation metrics suggest limited attractiveness due to a negative P/E ratio and low dividend yield.

Biotest Business Overview & Revenue Model

Company Description

Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. As of January 21, 2022, Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.

How the Company Makes Money

Biotest generates revenue primarily through the sale of its biopharmaceutical products, particularly those derived from human plasma. The company has established a robust revenue model that includes direct sales to hospitals, clinics, and healthcare providers worldwide. Key revenue streams include the sale of immunoglobulins, coagulation factors, and albumin products, which are critical in treating patients with specific medical conditions. Additionally, Biotest engages in strategic partnerships and collaborations with other pharmaceutical companies and research institutions to enhance its product offerings and expand its market reach. These partnerships often involve joint development agreements, licensing arrangements, and distribution agreements, contributing to the company's earnings and supporting its research and development efforts.

Biotest Financial Statement Overview

Summary

Biotest has shown revenue growth and improved operational efficiency. However, a decline in net profit margin and increased leverage are concerning. While cash flows have improved, cash conversion efficiency remains a challenge. The overall financial health is stable but with risks.

Income Statement

Biotest has shown a positive revenue growth from 2019 to 2024 with a compound annual growth rate. The gross profit margin improved significantly from the previous years but remains moderate. However, the net profit margin has fallen drastically in 2024 compared to 2023, indicating decreased profitability. The EBIT and EBITDA margins have shown improvement over the years, indicating better operational efficiency.

Balance Sheet

The debt-to-equity ratio has increased, indicating higher leverage, which could pose financial risk. The return on equity (ROE) declined in 2024 due to lower net income. The equity ratio has improved modestly, reflecting a stable capital structure.

Cash Flow

Free cash flow turned positive in 2024, showing improvement in cash management. However, the operating cash flow to net income ratio is low, indicating potential issues with cash conversion. The free cash flow to net income ratio has improved but still reflects challenges in converting income into cash.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	726.20M	684.60M	516.10M	515.60M	484.20M
Gross Profit	223.80M	280.30M	124.90M	80.70M	130.10M
EBITDA	120.40M	179.00M	28.30M	-17.70M	16.00M
Net Income	26.40M	127.00M	-31.60M	-63.30M	-31.40M
Balance Sheet
Total Assets	1.43B	1.41B	1.20B	1.10B	1.13B
Cash, Cash Equivalents and Short-Term Investments	119.50M	118.50M	136.60M	117.50M	89.20M
Total Debt	597.20M	689.80M	574.30M	496.30M	469.10M
Total Liabilities	903.30M	912.00M	831.90M	723.80M	689.70M
Stockholders Equity	530.70M	498.90M	371.10M	380.40M	441.60M
Cash Flow
Free Cash Flow	32.20M	-36.10M	-69.80M	15.70M	-43.70M
Operating Cash Flow	60.90M	-2.70M	-40.50M	33.90M	-16.70M
Investing Cash Flow	-25.70M	1.30M	-37.00M	-23.40M	-14.60M
Financing Cash Flow	-35.40M	-6.80M	89.60M	22.60M	42.00M

Biotest Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 29.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:BIO3, the sentiment is Negative. The current price of 29 is below the 20-day moving average (MA) of 29.62, below the 50-day MA of 29.85, and below the 200-day MA of 29.20, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 42.12 is Neutral, neither overbought nor oversold. The STOCH value of 37.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:BIO3.

Biotest Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ILM1	61 Neutral	340.76M	18.10	3.60%	―	7.02%	10.58%
DMP	60 Neutral	1.75B	16.12	17.62%	2.77%	3.98%	29.10%
EUZ	58 Neutral	1.09B	29.75	16.31%	2.88%	9.42%	9.54%
FYB	57 Neutral	390.46M	-2.30	-27.21%	―	-14.84%	-338.52%
BIO3	56 Neutral	€1.35B	44.96	-4.72%	0.14%	-18.82%	-113.85%
EVT	44 Neutral	1.05B	-6.77	-18.39%	―	-1.41%	9.05%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%